<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1521">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141357</url>
  </required_header>
  <id_info>
    <org_study_id>HBI-8000-305</org_study_id>
    <nct_id>NCT05141357</nct_id>
  </id_info>
  <brief_title>A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer</brief_title>
  <acronym>HBI-8000</acronym>
  <official_title>A Phase 2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Pembrolizumab for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HUYABIO International, LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HUYABIO International, LLC.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 study evaluates HBI-8000, a histone deacetylase inhibitor (HDACi) in combination&#xD;
      with pembrolizumab for the treatment of patients with advanced or metastatic non-small cell&#xD;
      lung cancer who possess programmed death ligand 1 (PD-L1) expression Tumor Proportion Score&#xD;
      (TPS) of 1% or greater.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From enrollment until disease progression or unacceptable toxicity, assessed up to 38 months approximately</time_frame>
    <description>The proportion of subjects achieving complete response or partial response according to RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>up to 38 months approximately</time_frame>
    <description>Time from 1st observation of objective response to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 38 months approximately</time_frame>
    <description>The proportion of subjects achieving complete response, partial response or stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>38 months</time_frame>
    <description>Time from the first dose of HBI-8000 to disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of HBI-8000 when administered in combination with standard dose and regimen of pembrolizumab</measure>
    <time_frame>From first enrolled up to 38 months, approximately</time_frame>
    <description>Number of participants experiencing treatment-emergent adverse events (TEAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>HBI-8000 in combination with pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HBI-8000 in combination with pembrolizumab</intervention_name>
    <description>Participants will take 30 mg of HBI-8000 by mouth every 3-4 days on a twice weekly (BIW) schedule. Pembrolizumab will be administered at 400 mg IV every 6 weeks (Q6W) or 200 mg IV every 3 weeks (Q3W) according to Prescribing Information and institution's prescribing practice for pembrolizumab.</description>
    <arm_group_label>HBI-8000 in combination with pembrolizumab</arm_group_label>
    <other_name>tudicdinostat</other_name>
    <other_name>Keytruda®</other_name>
    <other_name>pembrolizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathologically confirmed diagnosis of NSCLC with PD-L1 expression of ≥1% based on&#xD;
             FDA-approved test&#xD;
&#xD;
          -  No prior treatment with checkpoint inhibitors or more than one regimen of chemotherapy&#xD;
             including epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)&#xD;
             mutation directed therapy for advanced or metastatic disease&#xD;
&#xD;
          -  Disease must have at least 1 measurable target lesion by RECIST 1.1&#xD;
&#xD;
          -  Adequate major organ functions as evidenced by laboratory findings within 14 days&#xD;
             prior to first dose&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) ≤2 and must have a life expectancy of ≥12&#xD;
             weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of grade ≥3 hypersensitivity reactions to monoclonal antibodies&#xD;
&#xD;
          -  Participation in another interventional clinical trial within 28 days or less than 5&#xD;
             half-lives of investigational agent before the first dose&#xD;
&#xD;
          -  Recurrent pleural effusion requiring repetitive palliative thoracentesis within 3&#xD;
             months prior to study entry (except patients with a PleurX™ port)&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease or history of immune-mediated toxicity&#xD;
             leading to discontinuation of previous checkpoint inhibitor treatment should be&#xD;
             administered in (neo)adjuvant setting. Exceptions are for type I diabetes mellitus,&#xD;
             hyperthyroidism requiring hormone-replacement or skin only disorders (such as&#xD;
             vitiligo, psoriasis, or alopecia) not requiring systemic therapy&#xD;
&#xD;
          -  Active pneumonitis, history of non-infectious pneumonitis that required treatment with&#xD;
             steroids, or history of interstitial lung disease&#xD;
&#xD;
          -  Received approved live vaccines within 30 days of planned first dose. Intranasal&#xD;
             influenza vaccines (e.g. Flu-Mist) are not allowed, however inactivated viral vaccines&#xD;
             or vaccines based on subviral component are allowed&#xD;
&#xD;
          -  Any condition requiring chronic systemic treatment with either corticosteroids (&gt;10 mg&#xD;
             daily prednisone equivalents) or other immunosuppressive medications. And any steroids&#xD;
             use within 14 days of first dose except for inhaled or topical steroids.&#xD;
&#xD;
        Note: Other protocol-defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>M Tawashi, MSc</last_name>
    <phone>1-858-209-1695</phone>
    <email>mtawashi@huya.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>F Kabbinavar, MD</last_name>
    <phone>+1.858.798.8800--</phone>
    <email>fkabbinavar@huyabio.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBI-8000</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

